Continuing our clinical trials updates of 2024, in this instalment we look back at developments in life sciences research and development announced during the week of 15th to 19th January,
Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers.